JUVÉDERM VOLLURE™ XC came to market in the US in 2017 as the first and only hyaluronic acid dermal filler FDA approved for the correction of moderate to severe wrinkles and folds that lasts up to 18 months.
JUVÉDERM VOLLURE™ XC’s advanced VYCROSS® technology yields a custom-engineered injectable gel product which was studied in the nasolabial folds, the number-one dermal treatment area. It delivers a long-lasting result, up to 18 months*, that patients appreciate. This makes it perfect for filling in nasolabial folds and marionettes. It is very versatile and can be used in a number of additional treatment areas. For multiple treatment areas, Vollure is a great choice!
The news of this approval comes after an exciting clinical trial featuring the filler came to a close, revealing some promising findings. Patient satisfaction in the study was significant, with 82 percent of patients saying they were very satisfied after six months and 68 percent still claiming satisfaction at 18 months. JUVÉDERM VOLLURE XC™ is specifically tailored with a balance of gel firmness and low cohesivity, yielding a versatile formulation that adds subtle volume for the correction of moderate to severe facial wrinkles and folds.
Juvéderm Vollure XC features the same Vycross technology that Juvéderm Voluma XC (the filler used to plump the cheek area) and Juvéderm Volbella XC (the filler used in lip augmentation) uses. However, this time the Juvéderm Vollure XC is FDA-approved to use the Vycross technology in the nasolabial folds, which also happens to be the number-one dermal treatment area.
Juvéderm Vollure XC has been approved in Europe since 2013 under the name Juvéderm Volift and has had success in more than 80 countries outside of the U.S. since then.
Certificate has no cash value. Price of services subject to change if not redeemed within twelve (12) months of purchase. Amount paid for certificate never expires. Restrictions apply.